Public Meeting on Assessment of FDA Hiring and Retention
- November 30, 2017
- November 30, 2017
The Food and Drug Administration (FDA or the Agency) is holding a public meeting to share high-level findings from a recently-completed assessment of FDA’s hiring process, conducted by a qualified, independent contractor with expertise in assessing transformation of HR operations. The FDA recognizes that the critical work to protect public health is made possible in part by the Agency’s ability to attract and retain a talented, diverse, and dedicated workforce. As FDA continues to fulfil its strategic mission, it is imperative that the Agency identify and leverage the talent, skills, and diversity within—and outside of—the Agency.
These priorities are reflected in FDA’s plan to enhance its hiring and retention programs; recruit qualified candidates with diverse backgrounds, experiences, and talents; provide internal development opportunities; and further enhance the Agency’s ability to nurture a supportive and fair work environment. The public meeting will provide an update on FDA’s progress toward PDUFA and BsUFA user fee hiring and retention commitments, and solicit input on actions with regard to the hiring process.
Meeting Date and Time
November 30, 2017
9:00 a.m. to 12:00 p.m.
FDA White Oak Campus
10903 New Hampshire Avenue
Building 31 Conference Center
the Great Room (Room 1503, Section A)
Silver Spring, MD 20993-0002
The entrance for public meeting participants (non-FDA employees or contractors) is through Building 1, where routine security check procedures will be performed. For parking and security information, please refer to Public Meetings at the FDA White Oak Campus.
- Federal Register notice
- Public Meeting Agenda
- Initial Assessment of FDA Hiring and Retention Report
- November 30, 2017 Meeting Slides
- Official Transcript
If you wish to attend the public meeting (either in person or via webcast) and/or present at the meeting, please register by 12:00 noon on November 24, 2017.
If you need special accommodations due to a disability, please contact Dan Brounstein at 301-796-0674 or OMPTFeedback@fda.hhs.gov at least 7 days before the meeting.
FDA provided a free-of-charge live Webcast for viewing the public meeting. The archived Webcast can be found at Webcast.
Regardless of attendance at the public meeting, you can submit electronic or written comments to the public docket by January 15, 2018. Submit electronic comments to Regulations.gov. Submit written comments to the Division of Docket’s Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.
All comments must be identified with the docket number FDA-2017-23899. The FDA may post, without change, all comments received to Regulations.gov, including any personal information provided.
If you have questions about registering for the meeting, contact Dan Brounstein, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993, phone: 301-796-0674, email: OMPTFeedback@fda.hhs.gov.